PardesBiosciences.png
Pardes Biosciences Appoints New Chief Business and Strategy Officer
30 nov. 2021 07h00 HE | Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
29 nov. 2021 14h57 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV-2 (COVID-19) VIRUS Paris, 29 November, 2021, 8.45pm CET AB Science...
AB Science annonce le recrutement du premier patient dans l'étude de phase 2 évaluant l'activité antivirale du masitinib contre le virus SARS-CoV-2 (COVID-19)
29 nov. 2021 14h57 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE RECRUTEMENT DU PREMIER PATIENT DANS l’ETUDE DE PHASE 2 EVALUANT L’ACTIVITE ANTIVIRALE DU MASITINIB CONTRE LE VIRUS SARS-CoV-2 (COVID-19) Paris, 29 novembre...
QMDx.jpg
QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529
26 nov. 2021 07h37 HE | QuantuMDx Group Ltd
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union
25 nov. 2021 07h30 HE | BioNTech SE
NEW YORK and MAINZ, Germany, November 25, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® bei Kindern von 5 bis unter 12 Jahren in der Europäischen Union
25 nov. 2021 07h30 HE | BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 25. November 2021—Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass der Ausschuss für Humanarzneimittel...
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
22 nov. 2021 06h45 HE | BioNTech SE
Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified Data will support planned submissions for full regulatory...
Weitere Datenanalyse der Phase-3-Studie bestätigt Sicherheit und hohe Wirksamkeit des Pfizer-BioNTech COVID-19-Impfstoffs bei Jugendlichen im Alter von 12 bis 15 Jahren
22 nov. 2021 06h45 HE | BioNTech SE
Der Impfstoff von Pfizer und BioNTech wies in einer weiterführenden Analyse eine 100-prozentige Wirksamkeit gegen COVID-19 auf; es konnten keine schwerwiegenden Sicherheitsbedenken beobachtet...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
19 nov. 2021 08h25 HE | BioNTech SE
Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level of protection against COVID-19NEW YORK and MAINZ, Germany, November 19, 2021— Pfizer Inc. (NYSE:...
Canadian Air Purifier Company Airpura Donates HEPA Air Purifiers to Schools Across North America to Help Fight the Spread of COVID-19
11 nov. 2021 09h00 HE | Airpura
LAVAL, Quebec, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Research has shown that COVID-19 is primarily spread through airborne transmission. To stem the spread of the disease, the EPA has recommended the...